I can't let the Zenith webcast go out of my head.

On page 20 of the presentation it states the following;

Zenith has developed a BETi gene signature blood assay for measuring target modulation in the clinic. (I'm sure SanFran posted about this before)

The slide shows an inverted pyramid at the top and states "Differential micro array analysis in MV4-11 cells incorporating mechanistic rationale" and this is stage 1 of narrowing down from 600 genes to, at stage 4, 6 genes verified in the patients blood.

"Targeting patient subsets is the new frontier in oncology. BRD4 biology is prime for patient pre-selection". And Don says that the FDA likes this because it is moving toward patient specific treatment.

Well, I'm not a scientist but I am a science junky and for years the cancer experts have been talking about patient specific therapy or at least micro segmentation to very specific sub segments based on genetic traits.

Again, for me, it suggests Zenith is quite advanced in terms of methodologies and biochemical understanding and so much seems to launch off of their epigenetic focus.

JMO

Cheers

Toinv :)